Comparative Pharmacology
Head-to-head clinical analysis: ALTABAX versus CLEOCIN T.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTABAX versus CLEOCIN T.
ALTABAX vs CLEOCIN T
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retapamulin is a pleuromutilin antibiotic that selectively inhibits bacterial protein synthesis by interacting with the 50S ribosomal subunit, specifically at the L3 ribosomal protein and the peptidyl transferase center, thereby preventing peptide bond formation.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing peptide bond formation. It exhibits bacteriostatic activity against susceptible organisms.
1% ointment applied topically to affected area twice daily for 5 days. Total treatment area should not exceed 100 cm². Maximum single dose is 0.5 g per 100 cm².
Apply a thin film of 1% solution or gel twice daily to affected skin areas.
None Documented
None Documented
Terminal half-life is approximately 11-14 hours in adults after topical application, supporting twice-daily dosing.
The terminal elimination half-life in adults with normal renal and hepatic function is approximately 2-3 hours. In severe hepatic impairment, half-life may increase to 5-6 hours. No significant alteration in renal impairment.
Retapamulin is primarily eliminated via the fecal route (96.5% of dose), with minimal renal excretion (<0.5% of dose).
Clindamycin is primarily eliminated via hepatic metabolism and biliary excretion. Approximately 10% of the active drug is excreted renally, with the remainder as inactive metabolites in feces (biliary/fecal route).
Category C
Category C
Topical Antibiotic
Topical Antibiotic